Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: TENEX Clear all
Not listed Early Phase 1 Interventional

Dexamethasone to Target Stress and Immune System Mechanisms Underlying Alcohol Craving

NCT05305404
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Dexamethasone Oral, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

NCT01600885
View directory record Official record
Conditions
NMDA Receptor Function
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 11, 2026, 5:33 PM EDT
Recruiting Phase 2 Interventional

ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression

NCT06408246
View directory record Official record
Conditions
Depression
Interventions
Guanfacine, Sertraline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Palo Alto, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Platelet Rich Plasma Injection vs Percutaneous Tenotomy for Common Extensor Tendinopathy

NCT04384809
View directory record Official record
Conditions
Lateral Epicondylitis (Tennis Elbow)
Interventions
Leukocyte rich platelet rich plasma, Percutaneous Tenotomy
Biological · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Results available

Open-Label Pilot Study of Guanfacine-Extended Release for the Treatment of Cannabis Dependence

NCT01467999
View directory record Official record
Conditions
Cannabis Dependence
Interventions
Guanfacine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 11, 2026, 5:33 PM EDT
Withdrawn Phase 4 Interventional

Guanfacine Extended Release and Mindfulness Skills Therapy

NCT03258476
View directory record Official record
Conditions
Stress Disorder
Interventions
Guanfacine Extended Release, Mindfulness Skills Therapy, Placebo
Drug · Behavioral
Lead sponsor
UConn Health
Other
Eligibility
10 Years to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2021 · Synced Sep 11, 2026, 5:33 PM EDT
Not yet recruiting Not applicable Interventional

Ultrasound-Guided Percutaneous Needle Tenotomy (PNT) vs Percutaneous Ultrasonic Needle Tenotomy (PUT) for Gluteal Tendinosis

NCT07540806
View directory record Official record
Conditions
Tendinopathy, Tendinosis, Gluteal Tendinitis
Interventions
Percutaneous needle tenotomy (PNT), Percutaneous ultrasonic tenotomy (PUT, Tenex Device)
Procedure · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Not yet recruiting Phase 4 Interventional

Treating Young Children With Attention Deficit Hyperactivity Disorder

NCT07300956
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Guanfacine (GUA), Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 5 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Palo Alto, California • Boston, Massachusetts • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combining Varenicline and Guanfacine for Smoking Cessation

NCT04198116
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Guanfacine ER
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

NCT00997984
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 11, 2026, 5:33 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD

NCT02259517
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine, Lisdexamfetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 11, 2026, 5:33 PM EDT
Terminated Not applicable Interventional Results available

Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)

NCT02192398
View directory record Official record
Conditions
Chronic Pain
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy

NCT03865940
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Lidocaine, Guanfacine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

NCT01146002
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Guanfacine (sustained release)
Drug
Lead sponsor
Neurology Group of Bergen County, P.A.
Other
Eligibility
6 Years to 12 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 11, 2026, 5:33 PM EDT
Recruiting Not applicable Interventional

Randomized Controlled Trial (RCT) of Open Debridement Versus Tenex

NCT05757739
View directory record Official record
Conditions
Orthopedic Devices Associated With Misadventures
Interventions
Tenex Procedure, Open Debridement Surgical Intervention Treatment Plan
Procedure
Lead sponsor
Sean Mc Millan
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Burlington, New Jersey • Cherry Hill, New Jersey • Moorestown, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD

NCT01709695
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine Hydrochloride XR, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
8 Years to 15 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 11, 2026, 5:33 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Norepinephrine in Emotional Processing

NCT00109642
View directory record Official record
Conditions
Psychopathy, Mental Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
20 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

NCT01081145
View directory record Official record
Conditions
Attention-deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
27
States / cities
Dothan, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Omega-3 Supplementation to ADHD Medication in Children

NCT02204410
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
Interventions
Omega-3 Fatty Acid, ADHD Medication
Dietary Supplement · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

NCT03137082
View directory record Official record
Conditions
Alcohol Abstinence
Interventions
Guanfacine XR 3mgs/daily, Placebo (for guanfacine)
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Guanfacine on Delirium in Critically Ill Patients

NCT04578886
View directory record Official record
Conditions
Delirium
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01244490
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Atomoxetine Hydrochloride, Placebo Comparator
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
San Diego, California • Maitland, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 11, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Does Guanfacine Attenuate Stress-Induced Drinking?

NCT02164422
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Guanfacine 3mg/day, Guanfacine 1.5mg/day, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 7, 2021 · Synced Sep 11, 2026, 5:33 PM EDT